Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, United States.
J Appl Physiol (1985). 2023 Apr 1;134(4):1032-1037. doi: 10.1152/japplphysiol.00751.2022. Epub 2023 Mar 17.
There is current scientific and legal controversy about sports competition eligibility regulations for transgender athletes. In this case study, we quantified performances by an elite, transgender woman (male sex, female gender identity) college swimmer who competed in both the men's and women's National Collegiate Athletic Association (NCAA) categories. We also contextualized her performances with respect to world-record performances and contemporary elite college swimmers. These data demonstrate that the declines in freestyle swimming performances of a transgender woman after about 2 yr of reported feminizing gender-affirming hormone treatment (0.5% for the 100 to 7.3% for the 1,650 yard distance) are smaller than the observed sex-related differences in performance of top 200 world record performances in metric distances of similar durations (11.4% for the 100 m to 9.3% for the 1,500 m distance). Despite slower performances, the transgender woman swimmer experienced improvements in performance for each freestyle event (100 to 1,650 yards) relative to sex-specific NCAA rankings, including producing the best swimming time in the NCAA for the 500-yard distance (65 in the men's category in 2018-2019 to 1 in the women's, 2022). Similarly, NCAA-ranked male swimmers had no improvements in rank in the men's category during the same time frame. Our findings suggest that the performance times of the transgender woman swimmer in the women's NCAA category were outliers for each event distance and suggest that the transgender woman swimmer had superior performances relative to rank-matched swimmers. Our analysis may be useful as a framework for regulators considering participation guidelines, which promote fair competition for all athletes-irrespective of gender identity. This case study, longitudinal analysis of freestyle swimming performances before and after 2 yr of feminizing gender-affirming hormone therapy of an elite transgender woman (male sex, female gender identity), demonstrates superior performance relative to rank-matched female swimmers and a lower performance gap than previously observed between elite male and female swimmers.
目前,科学界和法律界对跨性别运动员参加体育比赛的资格规定存在争议。在本案例研究中,我们对一名参加过美国大学生体育协会(NCAA)男子和女子组比赛的精英跨性别女性(男性性别,女性性别认同)游泳运动员的表现进行了量化。我们还将她的表现与世界纪录和当代精英大学生游泳运动员的表现进行了对比。这些数据表明,在接受了大约 2 年的报告称能使女性化的性别肯定激素治疗后,跨性别女性的自由泳成绩下降幅度较小(100 米距离下降 0.5%,1650 米距离下降 7.3%),比观察到的类似持续时间的顶级 200 米世界纪录表现的性别相关差异要小(100 米距离下降 11.4%,1500 米距离下降 9.3%)。尽管成绩较慢,但这位跨性别女性游泳运动员在每个自由泳项目(100 米至 1650 米)中的表现都有所提高,相对于特定性别的 NCAA 排名,包括在 NCAA 中创造了 500 码距离的最佳游泳时间(2018-2019 年男子组为 65 秒,2022 年女子组为 1 秒)。同样,在同一时期,排名靠前的男性游泳运动员在男子组中的排名也没有提高。我们的研究结果表明,这位跨性别女性游泳运动员在女子 NCAA 组中的成绩在每个项目的距离上都是异常值,这表明她的表现优于排名相匹配的游泳运动员。我们的分析可以作为监管机构制定参赛指南的框架,这些指南旨在促进所有运动员的公平竞争,无论其性别认同如何。本案例研究对一名精英跨性别女性(男性性别,女性性别认同)在接受 2 年女性化性别肯定激素治疗前后的自由泳表现进行了纵向分析,结果表明,与排名相匹配的女性游泳运动员相比,她的表现更为出色,与此前观察到的精英男性和女性游泳运动员之间的表现差距也更小。